Drug Discovery World

AUGUST 29, 2024

For example, multiple RNA helicases are being targeted for cancer and viral infections before their catalytic properties are well understood. The Olink NPX Explore HT software can perform QC analysis and deliver Normalized Protein eXpression (NPX) values and raw data counts.

Small Molecule 147

Small Molecule Drugs Protein Expression Assay Development 147

DrugBank

JULY 24, 2024

These multifunctional small molecules are like tiny spies, hijacking the body’s natural protein degradation system to remove unwanted proteins. Similarly, PROTACs can target and degrade overexpressed proteins, offering a way to overcome drug resistance, a common issue in cancer treatment.

Small Molecule 84

Small Molecule Clinical Trials Drugs Therapies 84

Drug Discovery World

APRIL 30, 2024

Messenger RNA (mRNA) has come into focus within the drug discovery and development as an exciting tool to deliver genetic information. Its job is to carry coding information that is essential to the translation and processing of functional proteins.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Conversations in Drug Development Trends

MAY 30, 2024

This approach is facilitated by developing ASOs and RNA interference (RNAi) therapies, which target the various molecular and genetic mechanisms contributing to ALS pathophysiology and disease progression. However, work is needed before CRISPR-mediated treatments become possible, including a better understanding of the genes involved in ALS.

Treatment 81

Treatment Small Molecule Clinical Trials Therapies 81

Alta Sciences

APRIL 17, 2024

Oligonucleotide-Based Techniques Most oligonucleotide therapies act through antisense mechanisms and are directed against various RNA species. They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

Drug Discovery World

NOVEMBER 13, 2023

Michael Traxlmayr, PhD, Group leader, CD Laboratory for Next-Generation CAR T Cells, University of Natural Resources & Life Sciences, on: ‘Novel concepts to regulate CAR T cell activity with small molecule drugs in vivo’. Jana Langhoff, Tecan, on: ‘Opportunities and challenges of automating high throughput protein purification’.

Engineering 147

Engineering Science Bioinformatics Vaccine 147